The GLP-1 Discontinuation Crisis: Why Half of Patients Stop in Year One

Metriana Editorial · May 13, 2026 · 19 min read

Half of the patients who start a GLP-1 medication for weight loss will stop taking it before they finish their first year.

Let that number sit for a moment, because it should be central to every employer GLP-1 coverage decision being made right now.

These are not patients who completed a treatment course and achieved their goals. These are patients who started, encountered obstacles, and stopped — in many cases before the medication reached therapeutic maintenance doses, before behavioral change had time to take hold, and well before the health improvements that justify the investment had a chance to emerge.

For employers, this is not a peripheral concern about a subset of employees. It is the defining financial reality of unmanaged GLP-1 coverage. And what makes it particularly consequential is what the research now tells us about why it happens.

How many patients stop GLP-1 medications in year one?

The discontinuation data is consistent across multiple large studies, and it is not a minor leakage. It is a majority event.

A JAMA Network Open cohort study analyzing more than 125,000 adults with overweight or obesity initiating GLP-1 receptor agonists found that 46.5% of patients with type 2 diabetes and 64.8% of patients without type 2 diabetes discontinued within one year.¹ The significantly higher dropout rate among the obesity group — those using GLP-1 medications specifically for weight management, the primary employer benefit population — reflects a pattern documented across studies: when coverage for these medications is less consistent, and when the clinical infrastructure is less structured, persistence collapses.

A Danish population-based study of 77,310 first-time semaglutide users, presented at the European Association for the Study of Diabetes in September 2025, found that more than half had stopped using the medication after one year.² The study's lead researcher, Dr. Reimar Thomsen, was direct in his assessment: "The key takeaway is that stopping rates are simply very high — too high in my mind." He pointed to the need for "some good counseling in these patients from the beginning," noting that many people starting a GLP-1 drug for weight loss may not be well informed about the side effects that can occur, which can lead to early discontinuation.

Blue Cross Blue Shield Health Intelligence data shows approximately 30% of patients stop within the first 30 days alone. Prime Therapeutics pharmacy claims analysis found that only 14% of patients who start Wegovy remain on it after three years.

There is some evidence of improvement: pharmacy claims data from Prime Therapeutics showed that 63% of patients initiating Wegovy or Zepbound in early 2024 remained on therapy at one year, up from 40% in the 2023 cohort — an improvement attributed largely to supply stabilization and improving insurance coverage. But persistence declines sharply beyond year one, and the improvement is heavily correlated with structural and access factors that clinical support programs directly address.

Employer implication: Two in three employees using GLP-1 medications for weight loss — the core employer-benefit population — are stopping before the 12-month mark that research consistently identifies as when meaningful medical cost reductions begin to materialize.

Why do patients stop GLP-1 medications? The research breaks it down.

This is where the discontinuation story becomes an employer action item. The reasons patients stop are not random, and they are not uniformly inevitable. They fall into a small number of documented categories, most of which are directly addressable with structured clinical support.

Reason 1: Side effects — the leading driver of early dropout

Side effects, primarily gastrointestinal, are the most commonly documented reason for GLP-1 discontinuation across multiple large-scale studies. A Truveta real-world data analysis of GLP-1 discontinuations through December 2024 found that side effects accounted for 28.2% of all documented discontinuations — the single largest category — and noted that a substantial 21% of patients had multiple reasons for stopping, underscoring how tolerability issues compound with other barriers.³

The clinical scope of the GI side-effect problem is significant. Research on GLP-1 therapy in clinical practice shows gastrointestinal adverse events occur in roughly 40% to 70% of patients in the first year — nausea, vomiting, diarrhea, and constipation — and potentially as high as 85% in the second year, particularly during dose escalation phases. Severe GI events occur in an estimated 10% to 20% of users, and when they are severe enough, they precipitate cessation.

There are also important population-level variations in tolerability. Research shows that women experience nausea and vomiting at 2.5 times the rate of men — a significant finding for employers whose GLP-1-using populations skew female, and a strong argument for gender-informed clinical management protocols. Patients with a prior history of gastrointestinal medication were 9% more likely to discontinue within the first year; those with a psychiatric medication history were 12% more likely.

Critically, side effects drive early discontinuation: patients stopping due to side effects are disproportionately likely to do so within the first three months — before they have achieved meaningful weight loss and before adherence habits have formed.

What should employers understand about side-effect-driven dropout?

The most important clinical point is this: the majority of GI side effects that drive early discontinuation are manageable with proper clinical guidance and flexible dose titration. A "low and slow" titration approach — starting at the lowest dose and escalating only when the patient is tolerating the current dose — dramatically reduces the severity and duration of GI symptoms compared to standard escalation schedules. Dietary guidance on meal size, eating speed, fluid intake, and food choices during the titration phase can further mitigate symptoms.

The four major medical societies' joint advisory specifically identified modified dose titration, dietary modification, and proactive education on symptom management as core clinical tools for managing GI side effects during GLP-1 therapy.⁴ Post-bariatric surgical protocols — which have decades of experience managing similar physiological effects — offer proven strategies including small, frequent meals, slow eating, and fluid separation that translate directly to GLP-1 care.

Patients who stop because of nausea in weeks two through six are not, in most cases, experiencing a medication failure. They are experiencing a predictable physiological response to dose escalation that, with informed clinical support, most patients can move through. Without that support, they stop the medication and absorb none of the benefit. With it, they persist to maintenance doses where outcomes are achieved.

Employer implication: Side-effect-driven dropout is the most common documented reason GLP-1 patients quit in year one. It is also the most preventable with proactive clinical management. Every patient who stops because of unmanaged nausea in month two is a full prescription cost absorbed with zero clinical return.

Reason 2: Cost and insurance navigation failures

Cost is the other major documented driver — and the timing is distinct from side effects. Where side effects drive dropout early (within the first three months), cost-related discontinuation is more likely to occur later in the treatment arc, often when introductory coverage, co-pay coupons, or initial authorization periods expire.

A Cleveland Clinic study of patients who discontinued injectable semaglutide or tirzepatide for obesity found that 47.6% stopped for financial reasons, including insurance denial, expiration of a discount coupon, or out-of-pocket cost that became unaffordable.⁵ This finding — that cost is the dominant reason for discontinuation in a large clinical population — is consistent across studies and reflects a structural problem: insurance authorization processes for GLP-1 medications are frequently unclear, step therapy requirements are not consistently communicated at initiation, and prior authorization renewals can lapse without active management.

The practical consequence is that patients who have achieved initial weight loss and are approaching the point where medical benefits begin to materialize lose access to their medication due to navigation failures that a clinically managed program would have anticipated and addressed.

Reason 3: Expectation gaps and loss of motivation

A third category of discontinuation, less often quantified but consistently identified in clinical literature, involves patients who stop because their experience does not match what they expected. Patients often expect more rapid weight loss than GLP-1 medications typically produce in the early weeks. When the scale doesn't move as quickly as anticipated, or when the process feels harder than the marketing suggested, motivation erodes.

This expectation-outcome gap is directly addressable through pre-treatment counseling, realistic outcome framing, and proactive support during the phase between initiation and first measurable results — typically the highest-risk window for non-adherence. Patients who receive timely, structured guidance during this period persist longer; those who reach out to a provider only when something feels wrong are far more likely to self-discontinue.

What does stopping early actually cost — clinically and financially?

The clinical cost of early discontinuation is measurable. An observational study found that patients who discontinued semaglutide or tirzepatide within the first three months lost only 3.6% of their body weight — a result with limited clinical significance and insufficient to produce meaningful health improvements. Those who quit between three and twelve months fared somewhat better at 6.8% — well below the 10% to 15% threshold at which substantial comorbidity benefits typically emerge. Patients who remained adherent and reached therapeutic maintenance doses achieved weight loss comparable to clinical trials.⁶

The financial cost of early discontinuation is also now being directly quantified. Market analysis of the GLP-1 adherence sector estimates the economic cost of non-adherence at $8,400 to $12,600 per patient annually in wasted drug spend alone, reflecting the cost of prescriptions dispensed for patients who discontinued before producing clinical benefit.⁷ This does not include the downstream medical costs of regain, cardiovascular risk rebound, or comorbidity reassertion that follow discontinuation.

There is a specific employer cost dynamic worth examining here: 47.3% of patients with type 2 diabetes who discontinued their GLP-1 medications restarted within one year, compared to 36.3% of obesity patients. The restart pattern is higher among the diabetes population because coverage is more consistent — which produces the predictable restart cycle at full prescription cost, with the same partial-benefit outcome as the first episode. For the obesity population, the pattern is lower restart rates, meaning more patients are simply absorbing the weight regain without renewing the treatment investment. Both outcomes represent a failed program design, in different ways.

Employer implication: A patient who stops at week six has cost the same as one who persists to week 52 but has achieved a fraction of the clinical benefit. Early dropout is not just a clinical failure. It is a financial one, measured in prescriptions dispensed and benefits unrealized.

What happens to persistence when clinical support is in place?

The data on what structured clinical support does to persistence rates is among the most important — and most underutilized — evidence in the employer GLP-1 benefits literature.

Clinical studies report 34% to 42% improvements in 12-month medication persistence among patients enrolled in structured digital support programs versus those receiving no structured support. The mechanism is not complicated: patients who have proactive side-effect coaching, titration guidance, refill support, and behavioral check-ins get through the high-risk early dropout window. Patients who don't have those things stop.

Omada Health's clinical white paper on GLP-1 persistence, published in July 2025, provides a direct comparison from real-world program data.⁸ Members enrolled in their Enhanced GLP-1 Care Track showed 67% persistence at 12 months compared to the 47% to 49% observed in standard real-world evidence. Members who persisted through 12 months with that support achieved an average weight loss of 18.4%, compared to 11.9% in real-world evidence without structured support. Even members who eventually discontinued showed better weight loss outcomes (13.1%) than the real-world average without support (6.8%).

The four-society joint clinical advisory is explicit on what the evidence shows at the program level: patients receiving both GLP-1 therapy and structured nutrition and behavioral guidance achieved greater weight loss, better adherence, and were more likely to sustain weight loss after discontinuing medication compared to those receiving pharmacotherapy alone. Despite the known benefits, the advisory noted, most individuals prescribed GLP-1 medications do not currently receive adequate nutritional counseling or behavioral support.

The clinical leadership conclusion from IAPAM's February 2026 GLP-1 practice update says it directly: "The clinical evidence for integrated, chronic-disease care models continues to strengthen — GLP-1 therapy delivered as part of a comprehensive program produces better adherence and more durable outcomes than medication alone."

Employer implication: A 34% to 42% improvement in 12-month persistence is not a marginal gain. It is the difference between the majority of your GLP-1-covered employees reaching the point of meaningful clinical and financial return — and the majority not reaching it. That gap is the program design decision employers are making right now, whether they realize it or not.

What a persistence-focused GLP-1 program looks like

The research on why patients stop — and what prevents it — points to a specific program architecture. The components that differentiate a persistence-optimized program from a prescription benefit are not expensive or exotic. They are clinical fundamentals that the standard pharmacy benefit simply does not include.

Pre-treatment counseling and expectation setting. Patients who understand what the first six weeks will feel like — and who are told explicitly that GI symptoms are expected, temporary, and manageable — are meaningfully less likely to stop when those symptoms arrive. The Danish research team's prescription is simple: "You need to prepare people for what will happen." This happens once, at initiation. In most programs, it does not happen at all.

Slow, flexible dose titration with clinical oversight. The "low and slow" titration approach is the most direct clinical intervention for reducing GI-driven early dropout. It requires someone to be monitoring the patient and making titration decisions. Prescription-only models have no mechanism for this. Structured clinical programs do.

Proactive side-effect management protocols. Dietary guidance for managing nausea (small meals, slow eating, fluid separation, protein distribution), proactive monitoring during dose escalation, and a clear patient pathway for reporting symptoms and receiving support are the operational elements that keep patients in treatment through the tolerance-building phase.

Insurance and access navigation support. Cost-driven discontinuation, found to be nearly half of all documented dropouts in the Cleveland Clinic study, is largely a navigation failure, not a financial reality. Many patients whose coverage lapsed could have maintained access with prior authorization renewal support, appeals guidance, or timely identification of alternative coverage pathways. A managed program has staff accountable for this. A pharmacy benefit does not.

Monitoring through the high-risk windows. The first 30 days and the three-to-six-month period when titration challenges are highest are the two critical intervention windows. Proactive outreach at these points changes the persistence trajectory.

The questions employers should be asking

The discontinuation research creates a set of specific questions about what employer-sponsored GLP-1 benefits are actually delivering and what they are leaving unaddressed.

Does your GLP-1 benefit include any clinical support before the patient fills their first prescription? Pre-treatment counseling that sets expectations and prepares patients for GI symptoms is the single highest-leverage intervention for preventing early dropout. If it doesn't happen at initiation, it's not happening at the most important moment.

Who is managing dose titration? Standard GLP-1 prescribing follows fixed escalation schedules that drive more GI side effects than clinically necessary. Is there a clinical professional adjusting dosing based on each patient's tolerability, or is the patient following a package insert without support?

When an employee starts experiencing nausea in week three, what happens? Is there a proactive support channel where a clinical professional can provide dietary guidance, titration guidance, and reassurance? Or does the patient manage alone until they decide to stop?

Is anyone managing prior authorization renewals proactively? Cost-driven discontinuation after an initial authorization period is predictable and largely preventable. Does your program have someone accountable for monitoring and managing coverage continuity for GLP-1 patients?

What is your program's measured 12-month persistence rate? If your GLP-1 benefit design has never produced a persistence measurement, that absence is itself an answer. It means adherence has not been a managed outcome. It has been an assumption.

Do you know how much of your GLP-1 spend last year was absorbed by patients who stopped before achieving clinical benefit? The estimate of $8,400 to $12,600 in wasted drug spend per non-adherent patient makes this a directly calculable number. Understanding it is the first step toward changing it.

Metriana is built on The Mayo Clinic's precision medicine approach to weight management. Our platform combines evidence-based treatment protocols with behavioral support designed to produce lasting outcomes.